Renaissance Technologies LLC Has $151,000 Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Renaissance Technologies LLC lessened its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 41.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,200 shares of the company’s stock after selling 7,900 shares during the quarter. Renaissance Technologies LLC’s holdings in Stoke Therapeutics were worth $151,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quest Partners LLC acquired a new stake in shares of Stoke Therapeutics during the 2nd quarter valued at $29,000. Nisa Investment Advisors LLC grew its holdings in shares of Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after purchasing an additional 1,038 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Stoke Therapeutics in the second quarter valued at approximately $123,000. State Board of Administration of Florida Retirement System bought a new position in Stoke Therapeutics in the 1st quarter valued at approximately $141,000. Finally, BNP Paribas Financial Markets boosted its position in Stoke Therapeutics by 86.2% during the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock worth $193,000 after buying an additional 6,636 shares during the period.

Insider Activity

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the transaction, the insider now owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 11.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on STOK. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, September 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Thursday, August 8th. Finally, Wedbush restated an “outperform” rating and set a $17.00 price target on shares of Stoke Therapeutics in a report on Thursday, July 11th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $21.40.

Stoke Therapeutics Stock Performance

Stoke Therapeutics stock opened at $11.84 on Monday. The stock has a market capitalization of $617.11 million, a price-to-earnings ratio of -4.91 and a beta of 0.97. Stoke Therapeutics, Inc. has a 52-week low of $3.35 and a 52-week high of $17.58. The stock’s 50 day moving average price is $13.79 and its two-hundred day moving average price is $13.72.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The business had revenue of $4.83 million for the quarter, compared to analyst estimates of $3.33 million. On average, equities research analysts forecast that Stoke Therapeutics, Inc. will post -2.1 EPS for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.